April 24 (Reuters) - AstraZeneca and Merck's
ovarian and breast cancer drug Lynparza met a key secondary goal
in a late-stage study investigating its effectiveness in men
with prostate cancer and certain genetic mutations, the British
company said on Friday.
Lynparza was successful in helping patients with metastatic
castration-resistant prostate cancer and BRCA1/2 or ATM gene
mutations live longer compared with hormonal anticancer
therapies such as enzalutamide or abiraterone, new data https://www.astrazeneca.com/media-centre/press-releases/2020/lynparza-shows-overall-survival-in-prostate-cancer.html
from the study showed.
AstraZeneca had said https://www.reuters.com/article/us-astrazeneca-lynparza-trial/astrazenecas-lynparza-helps-prostate-cancer-patients-live-longer-study-idUSKCN1UX0L1
in August last year that the study had met its main goal.
(Reporting by Pushkala Aripaka in Bengaluru; editing by Patrick
Graham)
Astrazeneca (AZN)
